🔎 Trials Near Me

Home › Sleep Disorders › NCT07502443

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

RecruitingPhase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 (Brilliance NT2 Study 303)

Who can join

Ages 18 to 70 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Is willing and able, in the opinion of the Investigator, to understand and comply with protocol requirements, including the following: lifestyle considerations and restrictions, adherence to contraception guidance, adherence to actigraphy and diary requirements, if receiving treatment for OSA, adherence to primary OSA therapy over the 30 days prior to Visit 1, and throughout the study, including during overnight visits.
* Meets the diagnostic criteria of NT2 according to ICSD-3-TR guidelines, confirmed by diagnostic evaluations (either PSG/MSLT).

Exclusion Criteria:

* Has another comorbid sleep disorder or condition that may influence the sleep-wake cycle.
* Has a history or presence of other clinically significant (treated or untreated) illness, disease, abnormality, or surgical procedure that, in the opinion of the Investigator, might compromise participant safety, interfere with any study assessment, or affect the participant's ability to complete the study.
* Is currently enrolled in another interventional clinical trial or has received any investigational drug or used any interventional investigational device within 30 days prior to Visit 1. Participants previously enrolled in Study ALKS 2680-202 are not eligible for enrollment.
* Is currently pregnant, breastfeeding, or is planning to become pregnant during the study

About the study

The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.

What is being tested

Sponsor: Alkermes, Inc. · Participants: 176 · Started: Apr 22, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07502443

Locations in the U.S.

AlabamaAlkermes Investigational Site, Cullman
ArizonaAlkermes Investigational Site, Phoenix
CaliforniaAlkermes Investigational Site, Los Angeles
ColoradoAlkermes Investigational Site, Boulder
FloridaAlkermes Investigational Site, Brandon
Alkermes Investigational Site, Maimi
Alkermes Investigational Site, Winter Park
GeorgiaAlkermes Investigational Site, Macon
Alkermes Investigational Site, Stockbridge
KansasAlkermes Investigational Site, Kansas City
MassachusettsAlkermes Investigational Site, Newton
MichiganAlkermes Investigational Site, Lansing (Not yet recruiting)
Alkermes Investigational Site, Novi
North CarolinaAlkermes Investigational Site, Charlotte
Alkermes Investigational Site, Huntersville
OhioAlkermes Investigational Site, Cincinnati
PennsylvaniaAlkermes Investigational Site, Wyomissing
South CarolinaAlkermes Investigational Site, Columbia
TexasAlkermes Investigational Site, Austin
Alkermes Investigational Site, Frisco
Alkermes Investigational Site, San Antonio
Alkermes Investigational Site, Sugar Land

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.